pdufa.bio
CalendarDecisionsReadoutsPatents
Drug IndexStocksScreenerConferencesAdvisory Committees
StudiesRun-up by YearLearnGlossaryMethodologyAPIAccount
Pro
Home › PDUFA Calendar › INTE

INTE FDA calendar & decision history

Updated ·next FDA decision on the calendar
no upcoming catalyst on file · 1 past FDA decision

FDA decision history (1)

Mar 28, 2025✓ ApprovedFDA decision
Full PDUFA calendar →All FDA decisions →Phase readouts →
See the full 2026 PDUFA calendar →

This page aggregates INTE's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links to its source page. Facts and dates only; verify against primary FDA / SEC / company filings.

Common questions

When is the next FDA decision for INTE (INTE)?

INTE has no dated FDA catalyst on our calendar right now. That means no scheduled decision or readout date has been published in a source we can point to, not that none exists. We would rather say that than estimate one.

Has INTE (INTE) had an FDA decision before?

Yes, 1 in our archive: 1 approval(s) and 0 Complete Response Letter(s). The most recent was on March 28, 2025 and was an approval. Each one has its own page with the source document and the share-price reaction we measured.

How do stocks like INTE move into an FDA decision?

We have no measured history for INTE itself. Across the whole study of 1,839 FDA decisions, the median stock rose 17.7% at its best point in the 120 trading days before the decision, but was only 2.0% higher the day before it. Most of the move happened before the answer arrived and was largely given back.

Where does this INTE data come from?

FDA publications, company filings with the SEC, company press releases and ClinicalTrials.gov, with share prices measured from daily closing data. Every date and outcome links the document it came from. Where an outcome was inferred from the price reaction rather than read from a filing, the page says so on its face.